Activity Preview


AJP CME: July 2019 - Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental Illness

Activity Type:

  • Journal CME

Release Date: 7/1/2019

Expiration Date: 6/30/2021

  • AMA PRA Category 1: 1
  • Participation: 1



Objective: Case-control study design and disease heterogeneity may impede biomarker discovery in brain disorders, including serious mental illnesses. To identify biologically and/or behaviorally driven as opposed to diagnostically driven subgroups of individuals, the authors used hierarchical clustering to identify individuals with similar patterns of brain activity during a facial imitate/observe functional MRI task.

Methods: Participants in the Social Processes Initiative in Neurobiology of the Schizophrenia(s) study (N=179; 109 with a schizophrenia spectrum disorder and 70 healthy control participants) underwent MRI scanning at three sites. Hierarchical clustering was used to identify new data-driven groups of participants; differences on social and neurocognitive tests completed outside the scanner were compared among the new groups.


This activity is only available to AJP CME subscribers.

Don't have a subscription to AJP CME? Subscribe Now! 

  • AJP Subscriber – 12 Month CME Subscription: $155.00
  • Non AJP Subscriber – 12 Month CME Subscription: $310.00

If you have questions about AJP CME subscriptions, please contact

Educational Objective

The participant will review components of neuroimaging-based approaches to identify individuals at risk of developing mental illness.

Target Audience

This program is designed for all psychiatrists in clinical practice, residents in Graduate Medical Education programs, medical students interested in psychiatry, and other physicians who wish to advance their current knowledge of clinical medicine.

Estimated Time to Complete

Duration: 1 hour
Begin Date: July 1, 2019
End Date: June 30, 2021

How to Earn Credit

In order to earn CME credit, subscribers should read through the material presented in the article. After reading the article, complete the quiz and submit your evaluation and study hours (up to 1 AMA PRA Category 1 Credit™).  A score of 60% or higher is required to receive credit.


The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The APA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Title: Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental Illness

Authors: Colin Hawco, Ph.D., Robert W. Buchanan, M.D., Navona Calarco, B.A., Benoit H. Mulsant, M.D., Joseph D. Viviano, M.Sc., Erin W. Dickie, Ph.D., Miklos Argyelan, M.D., James M. Gold, Ph.D., Marco Iacoboni, M.D., Pamela DeRosse, Ph.D., George Foussias, M.D., Ph.D., Anil K. Malhotra, M.D., Aristotle N. Voineskos, M.D., Ph.D., for the SPINS Group

Affiliations: Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Toronto (C.H., N.C., B.H.M., J.D.V., E.W.D., G.F., A.N.V.); Department of Psychiatry, University of Toronto, Toronto (C.H., G.F., B.H.M., A.N.V.); Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Md. (R.W.B., J.M.G.); Division of Psychiatry Research, Zucker Hillside Hospital, Glen Oaks, N.Y. (M.A., P.D.R., A.K.M.); Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y. (M.A., P.D.R., A.K.M.); Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at the University of California, Los Angeles (M.I.).

Disclosures: Dr. Buchanan is an advisory board member for Avanir Pharmaceuticals, Astellas Pharma, Boehringer Ingelheim-RCV, Intracellular Therapies, Lundbeck, and Roche; he serves as a consultant for Takeda and Upsher-Smith Laboratories and as a data and safety monitoring board member for Pfizer. Dr. Mulsant has received research support from Brain Canada, the Canadian Institutes of Health Research, the Centre for Addiction and Mental Health (CAMH) Foundation, the Patient-Centered Outcomes Research Institute, NIH, Eli Lilly (medications for an NIH-funded clinical trial), Pfizer (medications for an NIH-funded clinical trial), Capital Solution Design (software used in a study by CAMH Foundation), and Happyneuron (software used in a study by Brain Canada); he owns stock in General Electric. Dr. Gold receives royalty payments from the Brief Assessment of Cognition in Schizophrenia. Dr. Foussias has served as an investigator on research sponsored by Medicure, Neurocrine Bioscience, and Hoffmann-La Roche; he has served on advisory boards for Hoffmann-La Roche and Takeda and has received speaker’s fees from Hoffmann-La Roche, Lundbeck, and Novartis. Dr. Malhotra receives consulting fees from Genomind, Biogen, and Concert Pharmaceuticals. The other authors report no financial relationships with commercial interests.

Discussion of unapproved or investigational use of products*: No.

*APA policy requires disclosure by CME authors of unapproved or investigational use of products discussed in CME programs. Off-label use of medications by individual physicians is permitted and common. Decisions about off-label use can be guided by scientific literature and clinical experience.

Program Planners

Ned H. Kalin, M.D. (Editor-in-Chief, AJP); Carolyn Rodriguez, M.D., Ph.D. (Deputy Editor, AJP); Michael D. Roy (Editorial Director, AJP); Michael A. Pogachar (Online Content Manager, Journals). Dr. Kalin has served as a consultant to the Board of Scientific Advisors, the Pritzker Neuropsychiatric Disorders Research Consortium, and the Skyland Trail Advisory Board and as Councilor, Society of Biological Psychiatry. Dr. Rodriguez has served as a consultant to Allergan, Blackthorn, Epiodyne, and Rugen. Mr. Roy and Mr. Pogachar report no financial relationships with commercial interests.

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher
  • Screen Resolution: 1024 x 768 pixels.

Minimum Requirements:

  • Windows PC:500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
  • Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact for questions about this course  |  Contact for technical assistance